CANbridge Pharmaceuticals Inc. (HKG:1228)

CANbridge Pharmaceuticals Revenue

CANbridge Pharmaceuticals had revenue of 27.94M CNY in the half year ending June 30, 2026, a decrease of -37.63%. This brings the company's total for the last twelve months to 55.68M, down -11.00% year-over-year. In the year 2025, CANbridge Pharmaceuticals had annual revenue of 49.98M, down -41.27%. That makes CANbridge Pharmaceuticals the 38,221st largest company in the world by revenue and 2,331st in Hong Kong.

• Revenue (ttm): 55.68M CNY
• Revenue Growth: -11.00%
• P/S Ratio: 16.08
• Revenue / Employee: 1.43M CNY
• Employees: 39
• Market Cap: 997.73M HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• Chinese Mainland 49.92M 99.9%
• Other Countries/Regions 59.00K 0.1%

Fiscal year ended Dec 31, 2025 See the full CANbridge Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	49.98M	-35.12M	-41.27%
Dec 31, 2024	85.10M	-17.77M	-17.27%
Dec 31, 2023	102.87M	23.90M	30.26%
Dec 31, 2022	78.97M	47.81M	153.43%
Dec 31, 2021	31.16M	19.13M	158.98%

Data Source: S&P Global Market Intelligence Last updated: Sep 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 2, 2026

Data Sources Report a data error